Page last updated: 2024-11-05

2,4-dichlorophenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,4-dichlorophenol: RN given refers to unlabeled parent+ cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2,4-dichlorophenol : A dichlorophenol that is phenol carrying chloro substituents at positions 2 and 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID8449
CHEMBL ID1143
CHEBI ID16738
SCHEMBL ID77936
MeSH IDM0045908

Synonyms (80)

Synonym
BIDD:ER0024
nci-c55345
wln: qr bg dg
nsc-2879
nsc2879
4,6-dichlorophenol
1-hydroxy-2,4-dichlorobenzene
CHEBI:16738 ,
2,4-dcp
nsc 2879
ccris 657
rcra waste no. u081
2,4-dichlorohydroxybenzene
brn 0742467
rcra waste number u081
ai3-00078
hsdb 1139
einecs 204-429-6
inchi=1/c6h4cl2o/c7-4-1-2-6(9)5(8)3-4/h1-3,9
phenol, 2,4-dichloro-
NCGC00091273-01
C02625
2,4-dichlorophenol
120-83-2
2,4-dichlorophenol, analytical standard
2,4-dichlorophenol, 99%
NCGC00091273-02
24-DICHLOROPHENOL ,
AC-11247
D0392
D3865
AKOS000118751
CHEMBL1143
BMSE000691
FT-0666601
NCGC00091273-04
NCGC00091273-03
2,4-dichloro-phenol
dtxsid1020439 ,
tox21_300040
NCGC00259138-01
tox21_201589
NCGC00253953-01
dtxcid70439
cas-120-83-2
4-06-00-00885 (beilstein handbook reference)
ec 204-429-6
unii-r669tg1950
r669tg1950 ,
FT-0610062
2,4-dichlorophenol [hsdb]
2,4-dichlorophenol [usp-rs]
2,4-dichlorophenol [mi]
SCHEMBL77936
2,4,-dichlorophenol
2,4-dichloro phenol
1,3-dichloro-4-hydroxybenzene
STR00302
J-507182
F1995-0250
5jc ,
mfcd00002169
2,4-dichlorophenol, pestanal(r), analytical standard
2,4-dichlorophenol, certified reference material, tracecert(r)
2,4-dichlorophenol, purum, >=97.0% (hplc)
2,4-dichlorophenol, united states pharmacopeia (usp) reference standard
2,4-dichlorophenic acid
2,4-dichlorophenate
2,4-dichlorophenol 100 microg/ml in methanol
2,4-dichlorophenol 10 microg/ml in methanol
2,4-dichlorophenol;4,6-dichlorophenol
2,4-d tp1
Q209205
AMY23192
HMS3740M09
CCG-272501
PD124041
EN300-19384
phen-3,5-d2-ol-d, 2,4-dichloro- (9ci)
Z104473682

Research Excerpts

Toxicity

Treated solutions of 2,4-dichlorophenol are less toxic on algae Pseudokirchneriella subcapitata if compared to not treated solutions. In the case of 3, 4-DCP only the samples collected during the runs at 20 and 60 min are capable of inhibiting the growth of the adopted organism.

ExcerptReferenceRelevance
" The transpiration of the trees was used to determine toxic effects."( Uptake, accumulation, phytotoxicity, and removal of 2,4-dichlorophenol in willow trees.
Kusk, KO; Trapp, S; Ucisik, AS, 2007
)
0.59
" Consequently, the SASS may be recommended as a promising configuration alternative for the waste streams containing toxic compounds."( Reducing effect of aerobic selector on the toxicity of synthetic organic compounds in activated sludge process.
Alkan, U; Eleren, SC, 2009
)
0.35
" Toxicity assessment on algae indicates that treated solutions of 2,4-dichlorophenol are less toxic on algae Pseudokirchneriella subcapitata if compared to not treated solutions whereas in the case of 3,4-dichlorophenol only the samples collected during the runs at 20 and 60 min are capable of inhibiting the growth of the adopted organism."( Oxidation of 2,4-dichlorophenol and 3,4-dichlorophenol by means of Fe(III)-homogeneous photocatalysis and algal toxicity assessment of the treated solutions.
Andreozzi, R; Di Somma, I; Marotta, R; Pinto, G; Pollio, A; Spasiano, D, 2011
)
0.98
" Consequently, the toxic activity of the test compounds was controlled by electrophilic index and electronic properties."( Dechlorination of chlorinated compounds by Trametes versicolor ATCC 200801 crude laccase and quantitative structure-activity relationship of toxicity.
Aytar, P; Çabuk, A; Gedikli, S; Sidir, İ; Sidir, YG, 2012
)
0.38
"2,4-Dichlorophenol (2,4-DCP) is an environmental pollutant exhibiting a wide spectrum of toxic effects."( Endoplasmic reticulum stress is involved in 2,4-dichlorophenol-induced hepatotoxicity.
Chen, P; Fu, J; Zhang, X; Zhang, Y, 2016
)
2.14

Compound-Compound Interactions

ExcerptReferenceRelevance
" In conclusion, at polarity-reversal interval of 24 h, electroremediation combined with activated bamboo charcoal was effective in simultaneous removal of 2,4-DCP and Cd from soil."( Simultaneous removal of 2,4-dichlorophenol and Cd from soils by electrokinetic remediation combined with activated bamboo charcoal.
Huang, ZH; Ma, JW; Wang, FY; Wang, H, 2010
)
0.67

Bioavailability

ExcerptReferenceRelevance
" The results clearly demonstrate that the differing impact of protein binding on the bioavailability of chemicals considerably influences their nominal and relative potencies in the presence of albumin."( Factors influencing nominal effective concentrations of chemical compounds in vitro: medium protein concentration.
Gülden, M; Mörchel, S; Seibert, H, 2002
)
0.31
" This research investigated 2,4-dichlorophenol (2,4-DCP) sequestration by the aquatic plant Lemna minor and evaluated contaminant release and bioavailability after plant death and cellular disruption."( Activity of Desulfitobacterium sp. strain Viet1 demonstrates bioavailability of 2,4-dichlorophenol previously sequestered by the aquatic plant Lemna minor.
Amos, BK; Löffler, FE; Saunders, FM; Tront, JM, 2006
)
0.85
" This approach appears to be a promising alternative treatment to reduce 2,4-DCP bioavailability and thus toxicity in the environment."( Reduction of 2,4-dichlorophenol toxicity to Pseudomonas putida after oxidative incubation with humic substances and a biomimetic catalyst.
Armenante, PM; Cozzolino, A; Hahn, D; Piccolo, A, 2007
)
0.71
"The complex and variable composition of natural sediments makes it very difficult to predict the bioavailability and bioaccumulation of sediment-bound contaminants."( Modelling 2,4-dichlorophenol bioavailability and bioaccumulation by the freshwater fingernail clam Sphaerium corneum using artificial particles and humic acids.
Simkiss, K; Taylor, MG; Verrengia Guerrero, NR, 2007
)
0.74
"The bioavailability of pollutants, pesticides and/or their degradation products in soil depends on the strength of their sorption by the different soil components, particularly by the clay minerals."( Sorption and desorption behavior of chloroanilines and chlorophenols on montmorillonite and kaolinite.
Gennaro, MC; Gianotti, V; Gosetti, F; Polati, S, 2006
)
0.33
" Our results indicate that geophagous earthworms may change sorption behavior and thus the bioavailability and transport of chlorophenols in soil."( Enhancement of chlorophenol sorption on soil by geophagous earthworms (Metaphire guillelmi).
Cui, Y; Guo, H; Ji, L; Ji, R; Shan, J; Xu, J; Zhou, W, 2011
)
0.37
" The inhibitory effects are supposed to be owing to limited activities of soil endogenous microorganisms, potential toxicities of CNTs to the microorganisms, and reduced bioavailability of 2,4-DCP in the presence of CNTs, even though a desorption hysteresis of 2,4-DCP on CNTs was not observed."( Inhibitory effects of carbon nanotubes on the degradation of 14C-2,4-dichlorophenol in soil.
Feng, J; Guo, H; Ji, R; Jiang, B; Shan, J; Wang, L; Zhou, W, 2013
)
0.63
" The oligomerization and partial dechlorination brought about by grinding, suggest a reduction in bioavailability and toxicity."( Birnessite-induced mechanochemical degradation of 2,4-dichlorophenol.
Mingelgrin, U; Nasser, A, 2014
)
0.66

Dosage Studied

The nanoadsorbent revealed high adsorption capacity. The removal percentages of 91 and 99% were found under optimal conditions for phenol and 2,4-dichlorophenol.

ExcerptRelevanceReference
" The influence of some operating conditions such as temperature, dosage of hydrogen peroxide and initial concentration of the chlorophenols was studied in absence of a catalyst."( Wet peroxide oxidation of chlorophenols.
Chamarro, E; Esplugas, S; Florczyk, M; García-Molina, V; López-Arias, M, 2005
)
0.33
" With the increase of the dosage of 2,4-dichlorophenol, stepwise improvement of biomass bioactivity and the reduction in activated sludge production were achieved simultaneously."( Impact of a metabolic uncoupler, 2,4-dichlorophenol on minimization of activated sludge production in membrane bioreactor.
Qiong, T; Song, L; Wenju, J; Yaozhong, L, 2010
)
0.92
" The effect of pH, catalyst dosage and dissolved iron on the degradation efficiency were studied."( [Degradation of organic pollutants by photo-Fenton-like system with hematite].
Gu, Y; He, Y; Huang, YP; Li, RP; Yang, H; Zhang, AQ; Zhang, Y, 2012
)
0.38
"0 g L(-1) nFe(3)O(4) was the optimal dosage in the presence of 3 g L(-1) Pd/Fe nanoparticles in our system, removing 76."( Enhanced dechlorination of 2,4-dichlorophenol by Pd/FeFe3O4 nanocomposites.
Baig, SA; Lv, X; Tang, J; Xu, J; Xu, X, 2013
)
0.69
" In addition, the removal kinetics of 2,4-DCP by Fe-Ni/CNTs were in agreement with a pseudo-first-order model, and the rate constants were dependent on a number of factors including the initial concentration of 2,4-DCP, the dosage of Fe-Ni/CNTs, pH value of the solution, and doping amount of Ni."( Synergistic effect and degradation mechanism on Fe-Ni/CNTs for removal of 2,4-dichlorophenol in aqueous solution.
Chun, Y; Fei, Z; Li, C; Liu, Z; Sun, Y; Zhang, A, 2019
)
0.74
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dichlorophenolAny chlorophenol carrying chloro substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
2,4-dichlorophenoxyacetate degradation314

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID886
SMAD family member 2Homo sapiens (human)Potency48.59500.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency48.59500.173734.304761.8120AID1346859
thyroid stimulating hormone receptorHomo sapiens (human)Potency15.84890.001318.074339.8107AID926; AID938
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency24.13870.001022.650876.6163AID1224893
retinoid X nuclear receptor alphaHomo sapiens (human)Potency48.59500.000817.505159.3239AID1159527
pregnane X nuclear receptorHomo sapiens (human)Potency68.03200.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency39.62820.000229.305416,493.5996AID743069; AID743075
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency30.82310.023723.228263.5986AID743222; AID743223
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency66.82420.000627.21521,122.0200AID651741
Cellular tumor antigen p53Homo sapiens (human)Potency68.03200.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (124)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID40623Inhibitory activity on germination of Bacillus subtilis PCI219 spores was determined.1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID26793Partition coefficient (logP)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID25611Dissociation constant (pKa)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID288184Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID288185Permeability coefficient through artificial membrane in presence of stirred water layer2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID40936Inhibition of Bacillus subtilis PCI219 spore germination, expressed as log 1/I501982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID26261Partition coefficient (logD7.2)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID288191Membrane retention in permeability experiment with artificial membrane2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID288192Partition coefficient, log P of the compound2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (527)

TimeframeStudies, This Drug (%)All Drugs %
pre-199031 (5.88)18.7374
1990's35 (6.64)18.2507
2000's193 (36.62)29.6817
2010's211 (40.04)24.3611
2020's57 (10.82)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.09 (24.57)
Research Supply Index6.31 (2.92)
Research Growth Index5.04 (4.65)
Search Engine Demand Index72.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (46.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.18%)6.00%
Case Studies4 (0.73%)4.05%
Observational0 (0.00%)0.25%
Other542 (99.09%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]